Boston ScientificBSX
About: Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Employees: 48,000
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
51% more first-time investments, than exits
New positions opened: 160 | Existing positions closed: 106
19% more repeat investments, than reductions
Existing positions increased: 546 | Existing positions reduced: 457
5% more capital invested
Capital invested by funds: $103B [Q2] → $109B (+$5.63B) [Q3]
4% more funds holding
Funds holding: 1,286 [Q2] → 1,340 (+54) [Q3]
3.08% less ownership
Funds ownership: 91.42% [Q2] → 88.35% (-3.08%) [Q3]
6% less funds holding in top 10
Funds holding in top 10: 36 [Q2] → 34 (-2) [Q3]
30% less call options, than puts
Call options by funds: $661M | Put options by funds: $944M
Research analyst outlook
19 Wall Street Analysts provided 1 year price targets over the past 3 months
19 analyst ratings
Bernstein Lee Hambright 100% 1-year accuracy 1 / 1 met price target | 15%upside $100 | Outperform Maintained | 24 Oct 2024 |
Morgan Stanley Patrick Wood 33% 1-year accuracy 3 / 9 met price target | 15%upside $100 | Overweight Maintained | 24 Oct 2024 |
RBC Capital Shagun Singh 55% 1-year accuracy 43 / 78 met price target | 13%upside $98 | Outperform Maintained | 24 Oct 2024 |
Wells Fargo Larry Biegelsen 60% 1-year accuracy 25 / 42 met price target | 13%upside $98 | Overweight Maintained | 24 Oct 2024 |
Citigroup Joanne Wuensch 69% 1-year accuracy 27 / 39 met price target | 13%upside $98 | Buy Maintained | 24 Oct 2024 |
Financial journalist opinion
Based on 30 articles about BSX published over the past 30 days
